Christopher Liu
Stock Analyst at Leerink Partners
(2.91)
# 1,680
Out of 4,752 analysts
5
Total ratings
100%
Success rate
34.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $4.63 | +288.77% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $24.11 | +11.99% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $85.92 | -51.12% | 1 | Aug 8, 2023 | |
| EXEL Exelixis | Initiates: Market Perform | $18 | $33.12 | -45.65% | 1 | Aug 8, 2023 |
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $4.63
Upside: +288.77%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $24.11
Upside: +11.99%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $85.92
Upside: -51.12%
Exelixis
Aug 8, 2023
Initiates: Market Perform
Price Target: $18
Current: $33.12
Upside: -45.65%